Pharmaceutical News

RSS

Health Canada accepts Paladin's Silenor NDS for review

Paladin Labs Inc. and Somaxon Pharmaceuticals, Inc. today announced that Paladin has filed a New Drug Submission (NDS) that has been accepted for review by Health Canada for Silenor (doxepin) for the treatment and symptomatic relief of insomnia.

23 Feb 2012

Depomed, Santarus reach agreement to resolve GLUMETZA patent litigation with Lupin

Santarus, Inc. and Depomed, Inc. today announced that they have entered into a settlement agreement with Lupin Ltd. and its subsidiary, Lupin Pharmaceuticals, Inc., to resolve pending patent litigation involving GLUMETZA 1000 mg and 500 mg.

23 Feb 2012

Statins can reduce risk of depression

Researchers at Charité - Universitätsmedizin Berlin and the University of California San Francisco have studied the link between medication taken for cardiovascular disease and the development of depression. In their studies, scientists have determined that a particular class of medication, i.e. statins, can reduce the risk of developing depression.

22 Feb 2012

Making a medicinewise choice between brands

Following reports the first generic version of atorvastatin will be hitting pharmacy shelves this week, NPS is urging consumers to be medicinewise when making a choice between medicine brands.

22 Feb 2012

FDA approves new supplies of drugs that are facing shortages

The United States Food and Drugs Administration (FDA) have approved new suppliers for two crucial cancer drugs, easing critical shortages that had been concerning patients and families particularly of the children with leukemia. But there are currently 283 separate prescription drugs in short supply or unavailable nationwide, and regulators and manufacturers say shortages are a long-term problem that will continue to scare patients and doctors.

22 Feb 2012

Counterfeit drugs on the Internet find their way into legitimate pharmacies

Criminal gangs are increasingly using the internet to market life-threatening counterfeit medicines and some have even turned up in legitimate outlets such as pharmacies, according to a review led by Dr Graham Jackson, editor of IJCP, the International Journal of Clinical Practice, and published in the March edition.

22 Feb 2012

Study aims to achieve early detection of heart disease

With the month of February designated as Heart Health Month, physician-researchers in the Division of Cardiology at the Los Angeles Biomedical Research Institute (LA BioMed) - Dr. Matthew Budoff and Dr. Ronald Oudiz - continue to pave the way with their efforts to develop treatments and therapies for conditions affecting the heart, and to help improve overall heart health.

22 Feb 2012

UMMS' iHeal project uses emerging technologies to detect drug cravings and intervene

Clinical researchers at the University of Massachusetts Medical School (UMMS) are combining an innovative constellation of technologies such as artificial intelligence, smartphone programming, biosensors and wireless connectivity to develop a device designed to detect physiological stressors associated with drug cravings and respond with user-tailored behavioral interventions that prevent substance use.

22 Feb 2012

FDA approves APP's preservative-free Methotrexate Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market preservative-free Methotrexate Injection, USP. APP currently manufactures Methotrexate Injection with preservative.

22 Feb 2012

Russian government's censorship of websites with harm reduction methods for drug users helps fuel HIV epidemic, IPS reports

"A recent government crackdown on Russian media, particularly online information portals specializing in health tips and harm reduction methods for drug users, has sparked widespread public opposition, with critics claiming that the 'draconian silencing' of public health advocates could worsen an already perilous health situation in the country," Inter Press Service reports.

22 Feb 2012

BioLineRx BL-7010 may reduce gluten toxicity in patients with celiac disease

BioLineRx, a biopharmaceutical development company, announced the publication of pre-clinical results demonstrating that BL-7010, an orally available treatment for celiac disease, reduces gluten toxicity (the negative effect of gluten on the patient's body).

22 Feb 2012

New chemical compound to treat brain damage from stroke

Researchers at the University of Copenhagen have designed, produced and patented a new chemical compound for the possible treatment of brain damage caused by stroke. The compound binds 1,000 times more effectively to the target protein in the brain than the potential drug currently being tested on stroke victims.

22 Feb 2012

Promising antibiotic alternative to fight bacteria that causes strep throat

Researchers have discovered a promising alternative to common antibiotics used to fight the bacteria that causes strep throat. In an article published in the Proceedings of the National Academy of Sciences, the scientists discussed how their discovery could fight the infection with a reduced risk of antibiotic resistance.

22 Feb 2012

EMA grants positive scientific opinion for Pyramax to treat malaria

Pyramax-, a fixed-dose combination of pyronaridine and artesunate, becomes the first antimalarial to be granted a positive scientific opinion from the European Medicines Agency (EMA) under Article 58. This once daily, 3-day treatment is indicated for acute, uncomplicated Plasmodium falciparum and blood-stage Plasmodium vivax malaria in adults and children over 20 kg.

22 Feb 2012

Weight gain or loss may also depend on medicines taken

Weight gain or loss may not always be caused by what you eat or how much you exercise. For some, it's the medicines you're taking.

22 Feb 2012

FDA grants orphan-drug designation to Arno's AR-42 for treatment of meningioma, schwannoma

Arno Therapeutics, Inc. announced today that its investigational compound, AR-42, has been granted orphan-drug designation by the U.S. Food and Drug Administration for the treatment of meningioma and schwannoma of the central nervous system.

21 Feb 2012

FDA to review rejected weight loss drug Qnexa

The weight loss pill Qnexa has been once rejected by the FDA over safety concerns. But this Wednesday it will get a second chance before an FDA advisory committee. Qnexa maker Vivus Inc. hopes something might come out of this second chance. The company will be submitting new safety data from patients who took Qnexa for a second year after completing a one-year clinical trial.

21 Feb 2012

Drug 'addicted' newborn the latest hysteria driven absurdity

The Florida Society of Pain Management Providers (www.Flspmp.org) feels it is vital to set the factual record straight in light of the mass deception used to foment a hysteria driven war on pain medications that now is threatening the health and welfare of Florida's chronic pain patients.

21 Feb 2012

AWMSG makes prostate cancer drug abiraterone available on the NHS

Cancer Research UK welcomes the news that the All Wales Medicines Strategy Group (AWMSG) has made prostate cancer drug abiraterone available on the NHS, paving the way for NICE to make a positive ruling when they publish their final guidance in May.

21 Feb 2012

Some answers about prescription psychiatric drugs

The circumstances of Whitney Houston's demise have dominated headlines and search trends since news outlets first reported of her death. Her struggle with addiction was covered extensively by the media, and even discussed candidly by Houston herself during several high-profile interviews.

20 Feb 2012